WallStSmart
HCM

HUTCHMED DRC

NASDAQ: HCM · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$12.87
-2.69% today

Updated 2026-06-05

Market cap
$1.96B
P/E ratio
4.29
P/S ratio
3.56x
EPS (TTM)
$2.65
Dividend yield
52W range
$11 – $20
Volume
0.0M

HUTCHMED DRC (HCM) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Revenue$50.43M$65.11M$86.97M$111.00M$134.51M$165.03M$22.37M$45.97M$87.33M$178.20M$216.08M$241.20M$214.11M$204.89M$227.98M$356.13M$426.41M$838.00M$630.20M$549.96M
Revenue growth (YoY)+29.1%+33.6%+27.6%+21.2%+22.7%-86.4%+105.5%+90.0%+104.1%+21.3%+11.6%-11.2%-4.3%+11.3%+56.2%+19.7%+96.5%-24.8%-12.7%
Cost of revenue$21.32M$27.66M$36.13M$44.59M$54.64M$74.16M$12.75M$22.21M$58.85M$110.78M$156.33M$175.82M$143.94M$160.15M$188.52M$258.23M$311.10M$384.45M$348.88M$337.24M
Gross profit$29.11M$37.45M$50.84M$66.41M$79.87M$91.11M$9.61M$23.76M$28.48M$67.43M$59.75M$65.38M$70.17M$44.74M$39.46M$97.89M$115.31M$453.55M$281.32M$212.72M
Gross margin57.7%57.5%58.5%59.8%59.4%55.2%43.0%51.7%32.6%37.8%27.7%27.1%32.8%21.8%17.3%27.5%27.0%54.1%44.6%38.7%
R&D$2.77M$5.64M$8.81M$3.86M$6.41M$7.29M$5.89M$4.48M$29.91M$47.37M$66.87M$75.78M$115.58M$91.94M$111.23M$207.45M$267.59M$303.06M$213.37M$164.15M
SG&A$21.38M$21.30M$12.71M$19.62M$21.58M$23.95M$30.91M$39.21M$50.02M$89.30M$92.17M$79.78M$64.30M$103.03M
Operating income$-5.38M$-9.72M$-14.23M$-4.61M$-2.21M$4.12M$-17.43M$-1.04M$-18.23M$-9.77M$-46.70M$-53.42M$-92.64M$-152.78M$-198.62M$-328.32M$-409.77M$18.38M$-43.70M$-54.73M
Operating margin-10.7%-14.9%-16.4%-4.2%-1.6%2.5%-77.9%-2.3%-20.9%-5.5%-21.6%-22.1%-43.3%-74.6%-87.1%-92.2%-96.1%2.2%-6.9%-10.0%
EBITDA$-2.51M$-5.92M$-9.58M$-46890.00$2.37M$11.32M$14.07M$12.05M$-17.01M$-7.76M$-43.39M$-49.50M$-82.06M$-135.13M$-190.61M$-207.96M$-401.11M$26.58M$-31.36M$-41.38M
EBITDA margin-5.0%-9.1%-11.0%-0.0%1.8%6.9%62.9%26.2%-19.5%-4.4%-20.1%-20.5%-38.3%-66.0%-83.6%-58.4%-94.1%3.2%-5.0%-7.5%
EBIT$-5.38M$-9.72M$-14.23M$-4.61M$-2.21M$6.76M$12.57M$11.08M$-18.23M$-9.77M$-45.70M$-52.08M$-85.65M$-140.07M$-196.67M$-215.15M$-409.77M$18.38M$-43.70M$-54.73M
Interest expense$388733.00$299147.00$527868.00$399374.00$402384.00$561030.00$1.16M$1.49M$1.52M$1.40M$1.63M$1.46M$1.01M$1.03M$787000.00$592000.00$652000.00$759000.00$2.87M$2.87M
Income tax$1963.00$837210.00$1.50M$2.07M$2.58M$3.14M$4.16M$1.05M$1.34M$1.60M$4.33M$3.08M$3.96M$3.27M$4.83M$11.92M$-283000.00$4.51M$7.19M
Effective tax rate-0.0%-5.1%-9.3%-30.9%-60.4%81.6%53.4%15.1%-4.3%16.7%27.0%-13.0%-5.6%-3.2%-4.0%-6.5%0.1%4.3%16.0%0.0%
Net income$-9.61M$-17.19M$-17.76M$-8.75M$-6.86M$710223.00$3.64M$5.92M$-32.82M$7.99M$11.70M$-26.74M$-74.81M$-106.02M$-125.73M$-194.65M$-360.83M$100.78M$37.73M$458.12M
Net income growth (YoY)-78.9%-3.3%+50.7%+21.5%+110.3%+412.2%+62.6%-654.8%+124.4%+46.4%-328.6%-179.8%-41.7%-18.6%-54.8%-85.4%+127.9%-62.6%+1114.2%
Profit margin-19.0%-26.4%-20.4%-7.9%-5.1%0.4%16.3%12.9%-37.6%4.5%5.4%-11.1%-34.9%-51.7%-55.2%-54.7%-84.6%12.0%6.0%83.3%

Frequently asked questions

What is HUTCHMED DRC's revenue?

HUTCHMED DRC's trailing twelve-month revenue is $548.51M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is HCM?

In its most recent fiscal year, HCM ran a gross margin of 38.68%, an operating margin of -9.95%, and a net margin of 83.30%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does HCM generate?

HCM produced $-79.01M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HCM's balance sheet healthy?

HCM holds $71.33M in cash and equivalents against $68.19M in long-term debt, on $1.24B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.